FOXO3 and ovarian carcinoma: Loss of FOXO3a has been observed in various cancers [14, 51], and its cellular localization and phosphorylation status are considered to be prognostic factors for acute myeloid leukemia [52], breast [15, 53], prostate [54], and ovarian cancer [55].